MedTrace Logo

Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF

NCT04296838 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-10-25

No results posted yet for this study

Summary

As a primary exploratory study, this study aims to evaluate the short-term effectiveness of intravitreal Conbercept injection in UME, and to explore the correlation between inflammatory factors like VEGF and the responsiveness to treatment.

Conditions

  • Uveitis
  • Macular Edema
  • Vascular Endothelial Growth Factor
  • Effect of Drugs

Interventions

DRUG

intravitreal injection of Conbercept

patients will receive intravitreal injection of Conbercept, and at the same time, aqueous humor sample will be obtained from the anterior chamber to measure the concentrations of cytokines.

Sponsors & Collaborators

  • Beijing Bethune public welfare fund

    collaborator UNKNOWN

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-12
Primary Completion
2020-04-12
Completion
2022-02-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04296838 on ClinicalTrials.gov